HomeMarketsSharesOutset Medical, Inc.

Trade Outset Medical, Inc. - OM CFD

Market is not available at the momentMarket information is presented
as of 2026-10-16T19:47:32+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.03
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02224 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02224%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00001 %
($0.00)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00001%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close4.07
Open4.02
1-Year Change-70.31%
Day's Range3.88 - 4.03

Trade Outset Medical, Inc. - OM

About Outset Medical Inc

Outset Medical, Inc. is a medical technology company that offers Tablo. Tablo is a mobile integrated hemodialysis solution for acute and home hemodialysis therapy. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels and allows providers to access a single platform from the hospital to the home. The Tablo cartridge is a single use consumable intended to facilitate extracorporeal blood purification for patients and consists of a pre-configured blood, saline, and infusion tubing. Tablo’s touch screen panel enables the user to navigate through the treatment with animations and non-technical language, tailored to both professional and non-professional users. Tablo’s cloud connectivity software enables an ecosystem of machine diagnostics and analytics, treatment instruction, monitoring and reporting, improved documentation and remote machine management. In addition, Tablo also delivers robust clinical care.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Outset Medical Inc revenues increased from $49.9M to $102.6M. Net loss applicable to common stockholders increased 66% to $131.9M. Revenues reflect Consoles segment increase of 98% to $65.1M, Consumables segment increase from $6.7M to $19.2M. Higher net loss reflects Sales and marketing - Balancing value increase of 46% to $59.2M (expense).

Latest shares articles

BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026
TAURON stock forecast
TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026
Puma stock forecast
Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026
Dino Polska stock forecast
Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready